{
    "xml": "<topic id=\"PHP81680\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/qutenza\" basename=\"qutenza\" title=\"Qutenza\">\n<title>Qutenza<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP84376\" outputclass=\"indicationsAndDose\" rev=\"1.12\" parent=\"/clinical-medicinal-product-information/qutenza\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Peripheral neuropathic pain in non-diabetic patients (under the supervision of a physician)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">To the skin</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP84390\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/qutenza\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (January 2011) that capsaicin 179&#8239;mg (8%) patch (<i>Qutenza</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who have not achieved adequate pain relief from, or who have not tolerated conventional first and second line treatments. Treatment should be under the supervision of a specialist in pain management.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81680",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/qutenza",
    "basename": "qutenza",
    "title": "Qutenza",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Peripheral neuropathic pain in non-diabetic patients (under the supervision of a physician)",
                        "html": "Peripheral neuropathic pain in non-diabetic patients (under the supervision of a physician)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "To the skin"
                    ],
                    "textContent": "To the skin",
                    "html": "To the skin"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (January 2011) that capsaicin 179 mg (8%) patch (Qutenza ) is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who have not achieved adequate pain relief from, or who have not tolerated conventional first and second line treatments. Treatment should be under the supervision of a specialist in pain management.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (January 2011) that capsaicin 179&#8239;mg (8%) patch (<i>Qutenza</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who have not achieved adequate pain relief from, or who have not tolerated conventional first and second line treatments. Treatment should be under the supervision of a specialist in pain management.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}